02 Jun CellProthera Prepares For Phase 3 Push As Regenerative Cardiology Moves Closer To Clinical Reality
Matthieu de Kalbermatten, CEO of CellProthera, discusses how new board appointments, manufacturing automation, and global clinical expertise are shaping the company’s strategy to advance ProtheraCytes® toward late stage development and future commercialisation.
BioSpectrum – Asia Edition | June 2026 | Ankit Kankar